Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yu N Lin'kova"'
Autor:
A I Tukach, S B Fitilev, I I Shkrebniova, A V Vozzhaev, V A Yakushev, R A Ivanov, Yu N Lin’kova, T V Chernovskaya
Publikováno v:
RUDN Journal of Medicine, Vol 0, Iss 2, Pp 114-118 (2014)
Treatment of hepatitis C is one of the most acute international healthcare problems. High standard in management of patients with HCV virus is combined therapy with pegylated interferon-a plus ribavirin. A necessity to develop new medications and to
Externí odkaz:
https://doaj.org/article/b3f82f65f8ea486bb2df1ec42ad50214
Autor:
E. L. Nasonov, V. I. Mazurov, A. M. Lila, T. V. Dubinina, I. Z. Gaydukova, S. A. Lapshina, A. A. Klimenko, D. V. Somov, S. A. Lukianov, D. M. Chudakov, I. V. Zvyagin, O. V. Britanova, M. A. Korolev, D. I. Abdulganieva, D. G. Krechikova, A. A. Kastanayan, L. V. Eliseeva, R. R. Samigullina, T. V. Povarova, O. V. Antipova, S. A. Smakotina, V. N. Soboleva, O. B. Nesmeyanova, T. V. Plaksina, N. F. Soroka, I. B. Vinogradova, A. P. Rebrov, T. V. Kropotina, A. L. Maslyanskiy, A. V. Zinkina-Orikhan, Yu. N. Lin’kova, P. S. Pukhtinskaia, M. A. Morozova, G. A. Vinderskaya
Publikováno v:
Научно-практическая ревматология, Vol 62, Iss 1, Pp 65-80 (2024)
The aim – to evaluate the clinical effectiveness, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of seniprutug (BCD-180) in patients with radiographic active axial spondyloarthritis (r-axSpA, or ankylosing spondylitis).Subjects and
Externí odkaz:
https://doaj.org/article/38cd433e63d04c6c9e4e85e988370a30
Autor:
O P Patrusheva, Yu. V. Trinitatskii, F. A. Khabirov, A. N. Boiko, L P Bosenko, V. V. Vasilovskii, T I Negrich, E V Lekomtseva, Kotov Sv, E V Parshina, M A Sherman, K B Tursunova, L I Volkova, A V Zinkina-Orikhan, M Ya Khavunka, L V Chichanovskaya, P. V. Timchenko, Yu N Lin'kova, S. V. Prokopenko, M. N. Zakharova, D V Sazonov
Publikováno v:
Neuroscience and Behavioral Physiology. 48:883-889
Objectives. To demonstrate equivalence of the efficacies of the drugs Teberif (BCD-033, interferon β-1a) and Rebif (interferon β-1a) in patients with remitting multiple sclerosis (RMS). Materials and methods. A multicenter, double-blind, placebo-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d72507f3b570c03d3198a0c9343f0a1
https://doi.org/10.1007/s11055-018-0643-z
https://doi.org/10.1007/s11055-018-0643-z
Autor:
D V Sazonov, L I Volkova, O P Patrusheva, L V Chichanovskaya, A V Zinkina-Orikhan, Kotov Sv, M A Sherman, M N Zakharova, T I Negrich, F. A. Khabirov, Yu V Trinitatskiy, L P Bosenko, A N Boyko, P. V. Timchenko, K B Tursunova, E V Parshina, M Ya Khavunka, Yu N Lin'kova, E V Lekomtseva, S. V. Prokopenko, V V Vasilovskiy
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 117(2. Vyp. 2)
To prove the equivalent efficacy of teberif (BCD-033, interferon beta-1) and rebif (interferon beta-1a) in patients with remitting multiple sclerosis (RMS).A multicenter double blind placebo-controlled comparative randomized III phase study included
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e93d0210c2394ef5581b6be0957c7270
https://pubmed.ncbi.nlm.nih.gov/28617368
https://pubmed.ncbi.nlm.nih.gov/28617368
Autor:
F. A. Khabirov, M Ya Khavunka, T I Negrich, E V Lekomtseva, Yu V Trinitatskiy, L I Volkova, S. V. Prokopenko, V V Vasilovskiy, E Yu Stukalina, D V Sazonov, O P Patrusheva, Kotov Sv, M A Sherman, A V Zinkina-Orikhan, L V Timchenko, E V Parshina, L P Bosenko, A N Boyko, L V Chichanovskaya, Yu N Lin'kova, M N Zakharova, I G Obukhova, Roman Ivanov
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 119:73
To evaluate efficacy, safety, and tolerability of the treatment with teberif/interferon β-1a, to analyze safety, tolerability and dynamics of key efficacy variables after switching from referent drug rebif to biosimilar teberif in patients with remi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46019bc35b7ad16dd208a674713fb402
https://doi.org/10.17116/jnevro20191192273
https://doi.org/10.17116/jnevro20191192273
Autor:
Kotov Sv, A N Boyko, Pavel Yakovlev, Yu N Lin'kova, Roman Ivanov, N A Totolian, O V Boyko, L N Prakhova, A V Zinkina-Orikhan, S G Shchur
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 119:87
To study the pharmacokinetics, pharmacodynamics, and immunogenicity of two intravenous dosing regimens of the new anti-B-cells drug BCD-132 (JSC BIOCAD, Russia) at ascending doses in patients with remitting multiple sclerosis.Twenty-four patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::649e0b42e35f0bf836bf388e8f117942
https://doi.org/10.17116/jnevro20191191087
https://doi.org/10.17116/jnevro20191191087
Autor:
A N Boyko, Yu N Lin'kova, A V Zinkina-Orikhan, K. Z. Bakhtiyarova, V. A. Dudin, T. V. Chernovskaya, L. G. Zaslavsky, Roman Ivanov, A. S. Fedulov, Ye. V. Parshina, N A Malkova
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 119:100
To evaluate the efficacy and safety of BCD 054 180 μg and 240 μg administered once every 2 weeks for the treatment of remitting multiple sclerosis compared to placebo and low dose interferon beta-1a (LIB) 30 μg administered once weekly. Results of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0517b8f1868609f9eef43a55878fde2f
https://doi.org/10.17116/jnevro201911910100
https://doi.org/10.17116/jnevro201911910100